β1, β2, and β3 adrenoceptors and Na+/H + Exchanger Regulatory Factor 1 expression in human bronchi and their modifications in cystic fibrosis

Florian Bossard, Émilie Silantieff, Emmanuelle Lavazais-Blancou, Amal Robay, Christine Sagan, Bertrand Rozec, Chantal Gauthier

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

To date, three b-adrenoceptor (b-AR) subtypes have been identified, but only β1-ARs and β2-ARs have been characterized in human lungs. Moreover, β2-ARs physically interact with the cystic fibrosis transmembrane conductance regulator (CFTR) through the Na +/H+ Exchanger Regulatory Factor 1 (NHERF1) protein.β3-ARs, which stimulate CFTR activity in transfected cells, have not been identified in human lungs. This study aimed (1) to characterize the presence of b-AR subtypes, especiallyβ3-AR, in human bronchi, and (2) to compare their expression as well as that of NHERF1 in non-cystic fibrosis (CF) versus advanced CF lung samples. In human non-CF bronchi, β1-AR, β2-AR,β3-AR, and NHERF1 transcripts and proteins were expressed mainly in bronchial epithelial cells. Those results were strengthened by the native expression of β1-AR, β2-AR, andβ3- AR in a human epithelial cell line, 16HBE14o2. All b-AR subtypes stimulated CFTR activity. In CF bronchi, we demonstrated β1-AR and b3-AR overexpression, and NHERF1 and β2-AR underexpression. The origin of this protein remodeling (involving the physical or functional absence of CFTR, infection, inflammation, or high adrenergic tone) deserves further investigation. These results evidence for the first time, to the best of our knowledge, the presence ofβ3-ARs in human bronchi, and suggest their usefulness as a putative new pharmacologic target in lung diseases where fluid homeostasis is altered. Furthermore, NHERF1 may be a new therapeutic target in patients with CF, to facilitate the trafficking of mutated CFTR to plasma membrane.

Original languageEnglish
Pages (from-to)91-98
Number of pages8
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Volume44
Issue number1
DOIs
Publication statusPublished - 1 Jan 2010
Externally publishedYes

Fingerprint

Cystic Fibrosis Transmembrane Conductance Regulator
Bronchi
Cystic Fibrosis
Adrenergic Receptors
Lung
Fibrosis
Epithelial Cells
Pulmonary diseases
Cell membranes
Adrenergic Agents
Proteins
Lung Diseases
sodium-hydrogen exchanger regulatory factor
Homeostasis
Cell Membrane
Amberlite XAD-2 resin
Fluids
Inflammation
Cell Line
Infection

Keywords

  • β-adrenergic receptor
  • Bronchus
  • Cystic fibrosis
  • Epithelium
  • NHERF1

ASJC Scopus subject areas

  • Cell Biology
  • Pulmonary and Respiratory Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

β1, β2, and β3 adrenoceptors and Na+/H + Exchanger Regulatory Factor 1 expression in human bronchi and their modifications in cystic fibrosis. / Bossard, Florian; Silantieff, Émilie; Lavazais-Blancou, Emmanuelle; Robay, Amal; Sagan, Christine; Rozec, Bertrand; Gauthier, Chantal.

In: American Journal of Respiratory Cell and Molecular Biology, Vol. 44, No. 1, 01.01.2010, p. 91-98.

Research output: Contribution to journalArticle

Bossard, Florian ; Silantieff, Émilie ; Lavazais-Blancou, Emmanuelle ; Robay, Amal ; Sagan, Christine ; Rozec, Bertrand ; Gauthier, Chantal. / β1, β2, and β3 adrenoceptors and Na+/H + Exchanger Regulatory Factor 1 expression in human bronchi and their modifications in cystic fibrosis. In: American Journal of Respiratory Cell and Molecular Biology. 2010 ; Vol. 44, No. 1. pp. 91-98.
@article{3405f19c36a44df7b7c42f95665a24e8,
title = "β1, β2, and β3 adrenoceptors and Na+/H + Exchanger Regulatory Factor 1 expression in human bronchi and their modifications in cystic fibrosis",
abstract = "To date, three b-adrenoceptor (b-AR) subtypes have been identified, but only β1-ARs and β2-ARs have been characterized in human lungs. Moreover, β2-ARs physically interact with the cystic fibrosis transmembrane conductance regulator (CFTR) through the Na +/H+ Exchanger Regulatory Factor 1 (NHERF1) protein.β3-ARs, which stimulate CFTR activity in transfected cells, have not been identified in human lungs. This study aimed (1) to characterize the presence of b-AR subtypes, especiallyβ3-AR, in human bronchi, and (2) to compare their expression as well as that of NHERF1 in non-cystic fibrosis (CF) versus advanced CF lung samples. In human non-CF bronchi, β1-AR, β2-AR,β3-AR, and NHERF1 transcripts and proteins were expressed mainly in bronchial epithelial cells. Those results were strengthened by the native expression of β1-AR, β2-AR, andβ3- AR in a human epithelial cell line, 16HBE14o2. All b-AR subtypes stimulated CFTR activity. In CF bronchi, we demonstrated β1-AR and b3-AR overexpression, and NHERF1 and β2-AR underexpression. The origin of this protein remodeling (involving the physical or functional absence of CFTR, infection, inflammation, or high adrenergic tone) deserves further investigation. These results evidence for the first time, to the best of our knowledge, the presence ofβ3-ARs in human bronchi, and suggest their usefulness as a putative new pharmacologic target in lung diseases where fluid homeostasis is altered. Furthermore, NHERF1 may be a new therapeutic target in patients with CF, to facilitate the trafficking of mutated CFTR to plasma membrane.",
keywords = "β-adrenergic receptor, Bronchus, Cystic fibrosis, Epithelium, NHERF1",
author = "Florian Bossard and {\'E}milie Silantieff and Emmanuelle Lavazais-Blancou and Amal Robay and Christine Sagan and Bertrand Rozec and Chantal Gauthier",
year = "2010",
month = "1",
day = "1",
doi = "10.1165/rcmb.2009-0372OC",
language = "English",
volume = "44",
pages = "91--98",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "1",

}

TY - JOUR

T1 - β1, β2, and β3 adrenoceptors and Na+/H + Exchanger Regulatory Factor 1 expression in human bronchi and their modifications in cystic fibrosis

AU - Bossard, Florian

AU - Silantieff, Émilie

AU - Lavazais-Blancou, Emmanuelle

AU - Robay, Amal

AU - Sagan, Christine

AU - Rozec, Bertrand

AU - Gauthier, Chantal

PY - 2010/1/1

Y1 - 2010/1/1

N2 - To date, three b-adrenoceptor (b-AR) subtypes have been identified, but only β1-ARs and β2-ARs have been characterized in human lungs. Moreover, β2-ARs physically interact with the cystic fibrosis transmembrane conductance regulator (CFTR) through the Na +/H+ Exchanger Regulatory Factor 1 (NHERF1) protein.β3-ARs, which stimulate CFTR activity in transfected cells, have not been identified in human lungs. This study aimed (1) to characterize the presence of b-AR subtypes, especiallyβ3-AR, in human bronchi, and (2) to compare their expression as well as that of NHERF1 in non-cystic fibrosis (CF) versus advanced CF lung samples. In human non-CF bronchi, β1-AR, β2-AR,β3-AR, and NHERF1 transcripts and proteins were expressed mainly in bronchial epithelial cells. Those results were strengthened by the native expression of β1-AR, β2-AR, andβ3- AR in a human epithelial cell line, 16HBE14o2. All b-AR subtypes stimulated CFTR activity. In CF bronchi, we demonstrated β1-AR and b3-AR overexpression, and NHERF1 and β2-AR underexpression. The origin of this protein remodeling (involving the physical or functional absence of CFTR, infection, inflammation, or high adrenergic tone) deserves further investigation. These results evidence for the first time, to the best of our knowledge, the presence ofβ3-ARs in human bronchi, and suggest their usefulness as a putative new pharmacologic target in lung diseases where fluid homeostasis is altered. Furthermore, NHERF1 may be a new therapeutic target in patients with CF, to facilitate the trafficking of mutated CFTR to plasma membrane.

AB - To date, three b-adrenoceptor (b-AR) subtypes have been identified, but only β1-ARs and β2-ARs have been characterized in human lungs. Moreover, β2-ARs physically interact with the cystic fibrosis transmembrane conductance regulator (CFTR) through the Na +/H+ Exchanger Regulatory Factor 1 (NHERF1) protein.β3-ARs, which stimulate CFTR activity in transfected cells, have not been identified in human lungs. This study aimed (1) to characterize the presence of b-AR subtypes, especiallyβ3-AR, in human bronchi, and (2) to compare their expression as well as that of NHERF1 in non-cystic fibrosis (CF) versus advanced CF lung samples. In human non-CF bronchi, β1-AR, β2-AR,β3-AR, and NHERF1 transcripts and proteins were expressed mainly in bronchial epithelial cells. Those results were strengthened by the native expression of β1-AR, β2-AR, andβ3- AR in a human epithelial cell line, 16HBE14o2. All b-AR subtypes stimulated CFTR activity. In CF bronchi, we demonstrated β1-AR and b3-AR overexpression, and NHERF1 and β2-AR underexpression. The origin of this protein remodeling (involving the physical or functional absence of CFTR, infection, inflammation, or high adrenergic tone) deserves further investigation. These results evidence for the first time, to the best of our knowledge, the presence ofβ3-ARs in human bronchi, and suggest their usefulness as a putative new pharmacologic target in lung diseases where fluid homeostasis is altered. Furthermore, NHERF1 may be a new therapeutic target in patients with CF, to facilitate the trafficking of mutated CFTR to plasma membrane.

KW - β-adrenergic receptor

KW - Bronchus

KW - Cystic fibrosis

KW - Epithelium

KW - NHERF1

UR - http://www.scopus.com/inward/record.url?scp=78650659673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650659673&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2009-0372OC

DO - 10.1165/rcmb.2009-0372OC

M3 - Article

C2 - 20203292

AN - SCOPUS:78650659673

VL - 44

SP - 91

EP - 98

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 1

ER -